Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ibezapolstat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 10,389Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Acurx Data Shows Gut-Selective Effect of DNA pol IIIC Antibiotics
    Acurx Data Shows Gut-Selective Effect of DNA pol IIIC Antibiotics

    28 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-new-data-on-its-dna-pol-iiic-inhibitor-antibiotics-demonstrating-a-potential-class-effect-of-gut-microbiome-selectivity-presented-at-idweek-2025-scientific-conference-302593922.html

    PR NEWSWIRE
    28 Oct 2025
    Share Share
    Acurx Gets EMA Positive Opinion on PIP for Ibezapolstat in CDI
    Acurx Gets EMA Positive Opinion on PIP for Ibezapolstat in CDI

    30 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-positive-opinion-from-ema-on-pediatric-investigation-plan-for-ibezapolstat-use-in-children-with-c-difficile-infection-302570470.html

    PR NEWSWIRE
    30 Sep 2025
    Share Share
    Acurx Publishes Data On Ibezapolstat's Gut Microbiome Effects
    Acurx Publishes Data On Ibezapolstat's Gut Microbiome Effects

    03 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-publication-of-nonclinical-in-vivo-data-differentiating-ibezapolstats-gut-microbiome-effects-from-other-anti-cdi-antibiotics-302386442.html

    PR NEWSWIRE
    03 Mar 2025
    Share Share
    Acurx publishes positive results on Ibezapolstat for CDI.
    Acurx publishes positive results on Ibezapolstat for CDI.

    24 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-publication-of-positive-results-from-an-in-silico-study-predicting-the-microbiome-restorative-potential-of-ibezapolstat-in-the-treatment-of-cdi-302382681.html

    PR NEWSWIRE
    24 Feb 2025
    Share Share
    Acurx Gets EMA Guidance For Ibezapolstat Ph3 For C. Difficile
    Acurx Gets EMA Guidance For Ibezapolstat Ph3 For C. Difficile

    06 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-receives-positive-regulatory-guidance-from-ema-for-ibezapolstat-phase-3-program-for-c-difficile-infection-cdi-302342404.html

    PR NEWSWIRE
    06 Jan 2025
    Share Share
    Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile
    Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile

    09 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-updates-phase-3-readiness-for-ibezapolstat-in-c-difficile-infection-based-on-recent-fda-and-ema-communications-302325768.html

    PR NEWSWIRE
    09 Dec 2024
    Share Share